

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

New Zealand No. 330400

International No. PCT/JP97/02859

**TO BE ENTERED AFTER  
ACCEPTANCE AND PUBLICATION**

Priority dates: 19.08.1996;

Complete Specification Filed: 07.05.1998

Classification: (6) C07H21/04; C07K14/00

Publication date: 28 May 1999

Journal No.: 1440

*International Patent Document Delivery, Translation and Mailing Specialists*  
Telephone (+44) 020 7412 7927/7981 Fax (+44) 020 7412 7930

REMOVABLE LABEL  
PATENT EXPRESS WISHES TO  
APOLOGISE FOR THE POOR  
COPY. THIS WAS CAUSED BY  
THE QUALITY OF THE ORIGINAL  
DOCUMENT.

**THE BRITISH LIBRARY**

**NEW ZEALAND  
PATENTS ACT 1953  
COMPLETE SPECIFICATION**

**Title of invention:****Novel dna and process for producing protein using the dna**

**Name, address and nationality of  
applicant(s) as in international  
application form:**

**SNOW BRAND MILK PRODUCTS CO., LTD. 1-1, Naebo-cho 6-chome, Higashi-ku,  
Sapporo-Shi, Hokkaido, 065, Japan**

330400

DESCRIPTION

NOVEL DNA AND PROCESS FOR PREPARING PROTEIN USING THE DNA

FIELD OF TECHNOLOGY

The present invention relates to a novel DNA and a process for preparing a protein which possesses an activity to inhibit osteoclast differentiation and/or maturation (hereinafter called osteoclastogenesis-inhibitory activity) by a genetic engineering technique using the DNA. More particularly, the present invention relates to a genomic DNA encoding a protein OCIF which possesses an osteoclastogenesis-inhibitory activity and a process for preparing said protein by a genetic engineering technique using the genomic DNA.

BACKGROUND OF THE INVENTION

Human bones are constantly repeating a process of resorption and formation. Osteoblasts controlling formation of bones and osteoclasts controlling resorption of bones take major roles in this process. Osteoporosis is a typical disease caused by abnormal metabolism of bones. This disease is caused when bone resorption by osteoclasts exceeds bone formation by osteoblasts. Although the mechanism of this disease is still to be elucidated completely, the disease causes the bones to ache, makes the bones fragile, and may result in fracturing of the bones. As the population of the aged increases, this disease results in an increase in the number of bedridden aged people which becomes a social problem. Urgent development of a therapeutic agent for this disease is strongly desired. Disease due to a

330400

decrease in bone mass is expected to be treated by controlling bone resorption, accelerating bone formation, or improving balance between bone resorption and formation.

Osteogenesis is expected to be increased by accelerating proliferation, differentiation, or activation of the cells controlling the bone formation, or by controlling proliferation, differentiation, or activation of the cells involved in bone

resorption. In recent years, strong interest has been directed to physiologically active proteins (cytokines) exhibiting such activities as described above, and energetic research is ongoing on this subject. The cytokines which have been reported to accelerate proliferation or differentiation of osteoblasts include the proteins of fibroblast growth factor family (FGF: Rodan S. B. et al., Endocrinology vol. 121, p 1917, 1987), insulin-like growth factor I (IGF-I: Hock J. M. et al., Endocrinology vol. 122, p 254, 1988), insulin growth factor II (IGF-II: McCarthy T. et al., Endocrinology vol. 124, p 301, 1989), Activin A (Centrella M. et al., Mol. Cell. Biol., vol. 11, p 250, 1991), transforming growth factor- $\beta$ , (Noda M., The Bone, vol. 2, p 29, 1988), Vasculotropin (Varonique M. et al., Biochem. Biophys. Res. Commun., vol. 199, p 380, 1994), and the protein of heterotopic bone formation factor family (bone morphogenic protein; BMP: BMP-2; Yanaguchi A. et al., J. Cell Biol. vol. 113, p 682, 1991, OP-1; Sampath T. K. et al., J. Biol. Chem. vol. 267, p 20532, 1992, and Knutsen R. et al., Biochem. Biophys. Res. Commun. vol. 194, P 1352, 1993).

On the other hand, as the cytokines which suppress

330400

differentiation and/or maturation of osteoclasts, transforming growth factor- $\beta$  (Chenu C, et al., Proc. Natl. Acad. Sci. USA, vol. 85, p 5683, 1988), interleukin-4 (Kasano K. et al., Bone-Miner., vol. 21, p 179, 1993), and the like have been reported. Further, as the cytokines which suppress bone resorption by osteoclast, calcitonin (Bone-Miner., vol. 17, p 347, 1992), macrophage colony stimulating factor (Hattersley G. et al., J. Cell. Physiol. vol. 137, p 199, 1988), interleukin-4 (Watanabe, K. et al., Biochem. Biophys. Res. Commun. vol. 172, P 1035, 1990), and interferon- $\gamma$  (Gowen M. et al., J. Bone Miner. Res., vol. 1, p 46.9, 1986) have been reported.

These cytokines are expected to be used as agents for treating diseases accompanying bone loss by accelerating bone formation or suppressing bone resorption. Clinical tests are being undertaken to verify the effect of improving bone metabolism of some cytokines such as insulin-like growth

factor-I and the heterotopic bone formation factor family. In addition, calcitonin is already commercially available as a therapeutic agent for osteoporosis and a pain relief agent. At present, drugs for clinically treating bone diseases or shortening the period of treatment of bone diseases include activated vitamin D<sub>3</sub>, calcitonin and its derivatives, and hormone preparations such as estradiol agent, ipriflavon or calcium preparations. These agents are not necessarily satisfactory in terms of the efficacy and therapeutic results. Development of a novel therapeutic agent which can be used in

330400


M. et al., Biochem. Biophys. Res. commun. vol.199, p380, 1994), and bone morphogenic protein (BMP:BMP-2; Yamaguchi, A et al., J. Cell Biol. vol. 113, p682, 1991, OP-1; Sampath T.K. et al., J. Biol. Chem. vol. 267, p20532, 1992, Knutsen R. et al., Biochem. Biophys. Res. Commun. vol. 194, p1352, 1992) were reported.

[0004]

On the other hand, as a cytokine inhibiting osteoclast formation, that is, differentiation and/or maturation of osteoclast, transforming growth factor- $\beta$  (Chenu C. et al., Proc. Natl. Acad. Sci. USA, vol.85, p5683, 1988) and interleukin-4 (Kasano K. et al., Bone-Miner., vol.21, p179, 1993) were reported. And as a cytokine inhibiting bone resorption induced by osteoclast, calcitonin (Bone Miner., vol.17, p347, 1992), macrophage colony-stimulating factor (Hattersley G. et al., J. Cell. Physiol. vol.137, p199, 1988), interleukin-4 (Watanabe, K. et al., Biochem. Biophys. Res. Commun., vol.172, p1035, 1990) and interferon- $\gamma$  (Gowen M. et al., J. Bone Miner. Res., vol.1, p469, 1986) were reported.

[0005]

These cytokines are expected to improve osteopenia by stimulating bone formation and inhibiting of bone resorption and clinical trial of some of the above-mentioned cytokines such as insulin like growth factor-I and cytokine of bone morphogenic protein family are being carried out as agents improving bone metabolism. Calcitonin has been already used as a therapeutic agent for osteoporosis or a pain relieving agent. In addition, for the treatment of metabolic bone diseases and for shortening treatment duration, active vitamin D<sub>3</sub>, calcitonin and analogue



330400

thereof, hormones such as estradiol, ipriflavone or calcium agent etc. is clinically used at present. However, by these therapeutic methods, effects of the treatment is not necessarily satisfactory. Therefore, development of a novel therapeutic agent is desired in replace of the above methods.

[0006]

[Problems to be Solved by the Invention]


Considering these situations, the present inventors have eagerly studied and found that OCIF protein having an inhibitory activity on osteoclast formation was already recovered from culture medium of human embryonic lung fibroblast cell line IMR-90(ATCC deposit number is CCL186) (PCT/JF96/00374). Further, the present inventors have studied on the origin of OCIF having an inhibitory activity on osteoclast formation and determined base sequence of genomic DNA of human originated OCIF. An object of the present invention is to provide a genomic DNA encoding OCIF protein having an inhibitory activity on osteoclast formation and a method of preparing said protein by genetic engineering manipulation.

[0007]

[Means to Solve the Problem]

The present invention relates to a genomic DNA encoding protein OCIF having an inhibitory activity on osteoclast formation and a method of preparing said protein thereby by genetic engineering manipulation.

The DNA of the present invention comprises base sequence of



immunological diagnosis of such diseases.

330400

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a result of Western Blotting analysis of the protein obtained by causing genomic DNA of the present invention to express a protein in Example 4 (iii), wherein lane 1 indicates a size marker, lane 2 indicates the culture broth of COS7 cells in which a vector pWESRaOCIF (Example 4 (iii)) has been transfected, and lane 3 is the culture broth of COS7 cell in which a vector pWESRa(control) has been transfected.

#### BEST MODE FOR CARRYING OUT THE INVENTION

The genomic DNA encoding the protein OCIF which exhibits osteoclastogenesis-inhibitory activity in the present invention can be obtained by preparing a cosmid library using a human placenta genomic DNA and a cosmid vector and by screening this library using DNA fragments which are prepared based on the OCIF cDNA as a probe. The thus-obtained genomic DNA is inserted into a suitable expression vector to prepare an OCIF expression cosmid. A recombinant type OCIF can be obtained by transfecting the genomic DNA into a host organism such as various types of cells or microorganism strains and causing the DNA to express a protein by a conventional method. The resultant protein exhibiting osteoclastogenesis-inhibitory activity (an osteoclastogenesis-inhibitory factor) is useful as an agent for the treatment and improvement of diseases involving a decrease in bone mass such as osteoporosis and other diseases relating to bone metabolism abnormality and also as an antigen to prepare antibodies for establishing immunological diagnosis of such



330400

diseases. The protein of the present invention can be prepared as a drug composition for oral or non-oral administration. Specifically, the drug composition of the present invention containing the protein which is an osteoclastogenesis-inhibitory factor as an active ingredient can be safely administered to humans and animals. As the form of drug composition, a composition for injection, composition for intravenous drip, suppository, nasal agent, sublingual agent, percutaneous absorption agent, and the like are given. In the case of the composition for injection, such a composition is a mixture of a pharmacologically effective amount of the osteoclastogenesis-inhibitory factor of the present invention and a pharmaceutically acceptable carrier. The composition may further comprise amino acids, saccharides, cellulose derivatives, and other excipients and/or activation agents, including other organic compounds and inorganic compounds which are commonly added to a composition for injection. When an injection preparation is prepared using the osteoclastogenesis-inhibitory factor of the present invention and these excipients and activation agents, a pH adjuster, buffering agent, stabilizer, solubilizing agent, and the like may be added if necessary to prepare various types of injection agents.

The present invention will now be described in more detail by way of examples which are given for the purpose of illustration and not intended to be limiting of the present invention.

## Example 1

330400

< Preparation of a cosmid library >

A cosmid library was prepared using human placenta genomic DNA (Clontech; Cat. No. 6550-2) and pWE15 cosmid vector (Stratagene). The experiment was carried out following principally the protocol attached to the pWE15 cosmid vector kit of Stratagene Company. provided Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory (1989)) was referred to for common procedures for handling DNA, E. coli, and phage.

(i) Preparation of restriction enzyme digest of human-genomic DNA

Human placenta genomic DNA dissolved in 750 µl of a solution containing 10 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, and 100 mM NaCl was added to four 1.5 ml Eppendorf tubes (tube A, B, C, and D) in the amount of 100 µg each. Restriction enzyme MboI was added to these tubes in the amounts of 0.2 unit for tube A, 0.4 unit for tube B, 0.6 unit for tube C, and 0.8 unit for tube D, and DNA was digested for 1 hour. Then, EDTA in the amount to make a 20 mM concentration was added to each tube to terminate the reaction, followed by extraction with phenol/chloroform (1:1). A two-fold amount of ethanol was added to the aqueous layer to precipitate DNA. DNA was collected by centrifugation, washed with 70% ethanol, and DNA in each tube was dissolved in 100 µl of TE (10mM Tris-HCl (pH 8.0) + 1mM EDTA) buffer solution, hereinafter called TE). DNA in four tubes was combined in one tube and incubated for 10 minutes at 68°C. After cooling to room

330400

temperature, the mixture was overlayed onto a 10%-40% linear sucrose gradient which was prepared in a buffer containing 20 mM Tris-HCl (pH 8.0), 5mM EDTA, and 1M NaCl in a centrifuge

tube (38 ml). The tube was centrifuged at 26,000 rpm for 24 hours at 20°C using a rotor SRP28SA manufactured by Hitachi, Ltd. and 0.4 ml fractions of the sucrose gradient was collected using a fraction collector. A portion of each fraction was subjected to 0.4% agarose electrophoresis to confirm the size of DNA. Fractions containing DNA with a length of 30 kb (kilo base pair) to 40 kb were thus combined. The DNA solution was diluted with TE to make a sucrose concentration to 10% or less and 2.5-fold volumes of ethanol was added to precipitate DNA. DNA was dissolved in TE and stored at 4°C.

(ii) Preparation of cosmid vector

The pWE15 cosmid vector obtained from Stratagene Company was completely digested with restriction enzyme BamHI according to the protocol attached to the cosmid vector kit. DNA collected by ethanol precipitation was dissolved in TE to a concentration of 1 mg/ml. Phosphoric acid at the 5'-end of this DNA was removed using calf small intestine alkaline phosphatase, and DNA was collected by phenol extraction and ethanol precipitation. The DNA was dissolved in TE to a concentration of 1 mg/ml.

(iii) Ligation of genomic DNA to vector and in vitro packaging

1.5 micrograms of genomic DNA fractionated according to size and 3 µg of pWE15 cosmid vector which was digested with

330400

restriction enzyme BamHI were ligated in 20  $\mu$ l of a reaction solution using Ready-To-Go T4DNA ligase of Pharmacia Company. The ligated DNA was packaged in vitro using Gigapack™ II packaging extract (Stratagene) according to the protocol. After the packaging reaction, a portion of the reaction mixture was diluted stepwise with an SM buffer solution and mixed with E. coli XL1-Blue MR (Stratagene) which was suspended in 10 mM  $MgCl_2$  to cause phage to infect, and plated onto LB agar plates containing 50  $\mu$ g/ml of ampicillin. The number of colonies produced was counted. The number of colonies per 1  $\mu$ l of packaging reaction was calculated based on this result.

(iv) Preparation of a cosmid library

The packaging reaction solution thus prepared was mixed with E. coli XL1-Blue MR and the mixture was plated onto agarose plates containing ampicillin so as to produce 50,000 colonies per agarose plate having a 15 cm of diameter. After incubating the plate overnight at 37°C, an LB culture medium was added in the amount of 3 ml per plate to suspend and collect E. coli cells. Each agarose plate was again washed with 3 ml of LB culture medium and the washing was combined with the original suspension of E. coli. The E. coli collected from all agarose plates was placed in a centrifuge tube, glycerol was added to a concentration of 20%, and ampicillin was further added to make a final concentration of 50  $\mu$ g/ml. A portion of the E. Coli suspension was removed and the remainder was stored at -80°C. The removed E. Coli was diluted stepwise and plated onto agar plates to estimate the number of colonies per 1 ml of

suspension.

Example 2

330400

<Screening of cosmid library and purification of colony>

A nitrocellulose filter (Millipore) with a diameter of 14.2 cm was placed on each LB agarose plate with a diameter of 15 cm which contained 50 µg/ml of ampicillin. The cosmid library was plated onto the plates so as to produce 50,000 colonies of *E. coli* per plate, followed by incubation overnight at 37°C. *E. coli* on the nitrocellulose filter was transferred to another nitrocellulose filter according to a conventional method to obtain two replica filters. According to the protocol attached to the cosmid vector kit, cosmid DNA in the *E. coli* on the replica filters was denatured with an alkali, neutralized, and immobilized on the nitrocellulose filter using a Stratalinker (Stratagene). The filters were heated for two hours at 80°C in a vacuum oven. The nitrocellulose filters thus obtained were hybridized using two kinds of DNA produced, respectively, from 5'-end and 3'-end of human OCIF cDNA as probes. Namely, a plasmid was purified from *E. coli* pKB/OIF10 (deposited at The Ministry of International Trade and Industry, the Agency of Industrial Science and Technology, Biotechnology Laboratory, Deposition No. FERM 3P-5267) containing OCIF cDNA. The plasmid containing OCIF cDNA was digested with restriction enzymes KpnI and EcoRI. Fragments thus obtained were separated using agarose gel electrophoresis. KpnI/EcoRI fragment with a length of 0.2 kb was purified using a QIAEX II gel extraction kit (Qiagen). This DNA was labelled with <sup>32</sup>p using the Megaprime DNA labelling

330400

System (Amersham) (5'-DNA probe). Apart from this, a BamHI/EcoRV fragment with a length of 0.2 kb which was produced from the above plasmid by digestion with restriction enzymes BamHI and EcoRV was purified and labeled with  $^{32}\text{P}$  (3'-DNA probe). One set of the replica filters described above was hybridized with the 5'-DNA probe and the other with the 3'-DNA probe. Hybridization and washing of the filters were carried out according to the protocol attached to the cosmid vector kit. Autoradiography detected several positive signals with each probe. One colony which gave positive signals with both probes was identified. The colony on the agar plate, which corresponding to the signal on the autoradiogram was isolated and purified. A cosmid was prepared from the purified colony by a conventional method. This cosmid was named pWEOCIF. The size of the human genomic DNA fragment contained in this cosmid was about 38 kb.

#### Example 3

< Determination of the nucleotide sequence of the human OCIF genomic DNA fragment >

##### (i) Subcloning of the OCIF genomic DNA fragment

Cosmid pWEOCIF was digested with restriction enzyme EcoRI. After the separation of the DNA fragments thus produced by electrophoresis using a 0.7% agarose gel, the DNA fragments were transferred to a nylon membrane (Hybond -N, Amersham) by the Southern blot technique and immobilized on the nylon membrane using Stratalinker (Stratagene). On the other hand, plasmid pBKOCIF was digested with restriction enzyme EcoRI and a 1.6

330400

kb fragment containing human OCIF cDNA was isolated by agarose gel electrophoresis. The fragment was labeled with  $^{32}\text{P}$  using the Megaprime DNA labeling system (Amasham).

Hybridization of the nylon membrane described above with the  $^{32}\text{P}$ -Labelled 1.6=kb OCIF cDNA, performed according to a conventional method, detected DNA fragments with a size of

6 kb, 4 kb, 3.6 kb, and 2.6 kb. These fragments hybridized with the human OCIF cDNA were isolated using agarose gel electrophoresis and individually subcloned into an EcoRI site of pBluescript II SK + vector (Stratagene) by a conventional method. The resulting plasmids were named respectively, pBSE 6, pBSE 4, pBSE 3.6, and pBSE 2.6.

(ii) Determination of the nucleotide sequence

The nucleotide sequences of the human OCIF genomic DNA fragments which were subcloned into the plasmid were determined using the ABI Dideoxy Terminator Cycle Sequencing Ready Reaction kit (Perkin Elmer) and the 373 Sequencing System (Applied Biosystems). The primers used for the determination of the nucleotide sequences were synthesized based on the nucleotide sequence of human OCIF

cDNA (Sequence ID No. 4 in the Sequence Table). The nucleotide sequences thus determined are given as the Sequences No. 1 and No. 2 in the Sequence Table. The Sequence ID No. 1 includes the first exon of the OCIF gene and the Sequence ID No. 2 includes the second, third, fourth, and fifth exons. A stretch of about 17 kb is present between the first and second exons.

Example 4

<Production of recombinant OCIF using COS-7 cells>

330400

(i) Preparation of OCIF genomic DNA expression cosmid

To express OCIF genomic DNA in animal cells, an expression unit of expression plasmid pCDL-SR $\alpha$ 296 (Molecular and Cellular Biology, vol. 8, P466-472, 1988) was inserted into cosmid vector pWE15 (Stratagene). First of all, the expression plasmid pCDL-SR $\alpha$ 296 was digested with a restriction enzyme Sal I to cut out expression unit with a length of about 1.7 kb which includes an SR $\alpha$ promotor, SV40 later splice signal, poly (A) addition signal, and so on. The digestion products were separated by agarose gel electrophoresis and the 1.7-kb fragment was purified using the QIAEX II gel extraction kit (Qiagen). On the other hand, cosmid vector pWE15 was digested with a restriction enzyme EcoRI and fragments were separated using agarose gel electrophoresis. pWE15 DNA of 8.2 kb long was purified using the QIAEX II gel extraction kit (Qiagen). The ends of these two DNA fragments were blunted using a DNA blunting kit (Takara Shuzo), ligated using a DNA ligation kit (Takara Shuzo), and transfected into E. coli DH5 $\alpha$  (Gibco BRL). The resultant transformant was grown and the expression cosmid pWESR $\alpha$  containing the expression unit was purified using a Qiagen column (Qiagen).

The cosmid pWE OCIF containing the OCIF genomic DNA fragment with a length of about 38 kb obtained in (i) above was digested with a restriction enzyme NotI to cut out the OCIF genomic DNA fragment of about 38 kb. After separation by agarose gel electrophoresis, the DNA fragment was purified using the QIAEX II gel extraction kit (Qiagen). On the other hand, the expression cosmid pWESR $\alpha$  was



330400

digested with a restriction enzyme EcoRI and the digestion product was extracted with phenol and chloroform, ethanol-precipitated, and dissolved in TE.

pWESR $\alpha$  digested with a restriction enzyme EcoRI and an EcoRI-XmnI-NotI adapter (#1105, #1156 New England Biolaboratory Co.) were ligated using T4 DNA ligase (Takara Shuzo Co., Ltd.). After removal of the free adapter by agarose gel electrophoresis, the product was purified using QIAEX gel extraction kit (Qiagen). The OCIF genomic DNA fragment with a length of about 37 kb, which was derived from the digestion with restriction enzyme NotI and the pWESR $\alpha$  to which the adapter was attached were ligated using T4 DNA ligase (Takara Shuzo). The DNA was packaged in vitro using the Gigapack packaging extract (Stratagene) and transfected to *E. coli* XL1-BlueMR (Stratagene). The resultant transformant was grown and the expression cosmid pWESR $\alpha$  OCIF which contained OCIF genomic DNA fragment was purified using a Qiagen column (Qiagen). The OCIF expression cosmid pWESR $\alpha$  OCIF was ethanol-precipitated, dissolved in sterile distilled water and used in the following analysis.

(ii) Transient expression of OCIF genomic DNA and measurement of OCIF activity

A recombinant OCIF was expressed as described below using the OCIF expression cosmid pWESR $\alpha$ OCIF obtained in (i) above and its activity was measured. COS-7 ( $8 \times 10^5$  cells/well) cells (Riken Cell Bank, RCB0539) were plated in a 6-well plate using DMEM culture medium (Gibco BRL) containing 10% fetal bovine serum (Gibco BRL). On the following day, the culture

330400

medium was removed and cells were washed with serum-free DMEM culture medium. The OCIF expression cosmid pWESR $\alpha$ OCIF which had been diluted with OPTI-MEM culture medium (Gibco BRL) was mixed with lipopectamine and the mixture was added to the cells in each well according to the attached protocol. The expression cosmid pWESR $\alpha$  was added to the cells in the same manner as a control. The amount of the cosmid DNA and Lipopectamine was respectively 3  $\mu$ g and 12  $\mu$ l. After 24 hours, the culture medium was removed and 1.5 ml of fresh EX-CELL 301 culture medium (JRH Bioscience) was added to each well. The culture medium was recovered after 48 hours and used as a sample for the measurement of OCIF activity. The measurement of OCIF activity was carried out according to the method described by Kumegawa, M. et al. (Protein, Nucleic Acid, and Enzyme, Vol. 34, p 999 (1989)) and the method of TAKAHASHI, N. et al. (Endocrinology vol. 122, p 1373 (1988)). The osteoclast formation from bone marrow cells isolated from mice aged about 17 days in the presence of activated vitamin D<sub>3</sub> was evaluated by the induction of tartaric acid resistant acidic phosphatase activity. The reduction of the acid phosphatase was measured and used as the activity of the protein which possesses osteoclastogenesis-inhibitory activity (OCIF). Namely, 100  $\mu$ l of a OCIF sample which was diluted with  $\alpha$ -MEM culture medium (Gibco BRL) containing  $2 \times 10^{-8}$  M activated vitamin D<sub>3</sub> and 10% fetal bovine serum was added to each well of a 96 well micro plate. Then,  $3 \times 10^5$  bone marrow cells isolated from mice (about 17-days old) suspended in 100  $\mu$ l of  $\alpha$ -MEM culture medium containing 10% fetal bovine serum

330400

were added to each well of the 96 well micro plate and cultured for a week at 37°C and 100% humidity under 5% CO<sub>2</sub> atmosphere. On days 3 and 5, 160 µl of the conditioned medium was removed from each well, and 160 µl of a sample which was diluted with α-MEM culture medium containing  $1 \times 10^{-6}$  M activated vitamin D<sub>3</sub> and 10% fetal bovine serum was added. On day 7, the cells were washed with a phosphate buffered saline and fixed with a ethanol/acetone (1:1) solution for one

minute at room temperature. The osteoclast formation was detected by staining the cells using an acidic phosphatase activity measurement kit (Acid Phosphatase, Leucocyte, Cat. No. 387-A, Sigma Company). A decrease in the number of cells positive to acidic phosphatase activity in the presence of tartaric acid was taken as the OCIF activity. The results are shown in Table 1, which indicates that the conditioned medium exhibits the similar activity to natural type OCIF obtained from the IMR-90 culture medium and recombinant OCIF produced by CHO cells.

330409

TABLE 1

Activity of OCIF in the conditioned medium of COS-7 cells.

Dilution	1/10	1/20	1/40	1/80	1/160	1/320
OCIF genomic DNA introduced	++	++	++	++	+	-
Vector introduced	-	-	-	-	-	-
Untreated	-	-	-	-	-	-

"++" indicates an activity inhibiting 80% or more of osteoclast formation, "+" indicates an activity inhibiting 30-80% of osteoclast formation, and "-" indicates that no inhibition of osteoclast formation is observed.

(iii) Identification of the product by Western Blotting

A buffer solution (10  $\mu$ l) for SDS-PAGE (0.5 M Tris-HCl, 20% glycerol, 4% SDS, 20  $\mu$ g/ml bromophenol blue, pH 6.8) was added to 10  $\mu$ l of the sample for the measurement of OCIF activity prepared in (ii) above. After boiling for 3 minutes at 100°C, the mixture was subjected to 10% SDS polyacrylamide electrophoresis under non-reducing conditions. The proteins were transferred from the gel to a PVDF membrane (ProBlott, Perkin Elmer) using semi-dry blotting apparatus (Biorad). The membrane was blocked and incubated for 2 hours at 37°C together with a horseradish peroxidase-labeled anti-OCIF antibody obtained by labelling the previously obtained anti-OCIF antibody with horseradish peroxidase according to a conventional method.

After washing, the protein which bound the anti-OCIF antibody was detected using the ECL system (Amasham). As shown in Figure 1, two bands, one with a molecular weight of about 120 kilo dalton and the other 60 kilo dalton, were detected in

330400

the supernatant obtained from the culture broth of COS-7 cells in which pWESR $\alpha$ OCIF was transfected. On the other hand, these two bands with a molecular weight of about 120 kilo dalton and 60 kilo dalton were not detected in the supernatant obtained from the culture broth of COS-7 cells in which pWESR $\alpha$ vector was transfected, confirming that the protein obtained was OCIF.

#### INDUSTRIAL APPLICABILITY

The present invention provides a genomic DNA encoding a protein OCIF which possesses an osteoclastogenesis-inhibitory activity and a process for preparing this protein by a genetic engineering technique using the genomic DNA. The protein obtained by expressing the gene of the present invention exhibits an osteoclastogenesis-inhibitory activity and is useful as an agent for the treatment and improvement of diseases involving a decrease in the amount of bone such as osteoporosis, other diseases resulting from bone metabolism abnormality such as rheumatism, degenerative joint disease, and multiple myeloma. The protein is further useful as an antigen to establish antibodies useful for an immunological diagnosis of such diseases.

#### NOTE ON MICROORGANISM

##### **Depositing Organization:**

The Ministry of International Trade and Industry, National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology

Address: 1-3, Higashi-1-Chome, Tsukuba-shi, Ibaraki-ken, Japan

[0024]

330400

Seq.Id.No.: 1

Length of sequence: 1316

Type of sequence: nucleic acid

Strandedness: 2

Topology: linear

Molecular type: genomic DNA(human OCIF genomic DNA-1)

Sequence:

CTGGAGACAT ATAACCTGAA CACTTGGCCC TGATGGGGAA GCAGCTCTGC AGGGACTTTT 60  
TCAGCCATCT GTAAACAATT TCAGTGGCAA CCCCGAACT GTAATCCATG AATGGGACCA 120  
CACTTTACAA GTCATCAAGT CTAACCTCTA GACCAGGGAA TTAATGGGGG AGACAGCCAA 180  
CCCTAGAGCA AAGTGCCAAA CTTCGTGCGA TAGCTTGAGG CTAGTGGAAA GACCTCCAGG 240  
AGGCTACTCC AGAAGTTCAG CGCGTAGGAA GCTCCGATAC CAATAGCCCT TTGATGATGG 300  
TGGGGTTGGT EAAGGGAACA GTGCTCCGCA AGGTTATCCC TCGCCACGCC AGTCCAATT 360  
TCACTCTGCA GATTCTCTCT GGCTCTAACT ACCCCAGATA ACAAGGAGTG AATGCAGAAT 420  
AGCACGGGCT TTAGGGCCAA TCAGACATTA GTTAGAAAAA TTCCTACTAC ATGGTTTATG 480  
TAAACTTGAA GATGAATGAT TGCGAACTCC CCGAAAAGGG CTCAGACAAT GCCATGCATA 540  
AAGAGGGGCC CTGTAATTG AGGTTTCAGA ACCCGAAGTG AAGGGGTCAG GCAGCCGGGT 600  
ACGGCGGAAA CTCACAGCTT TCGCCACGCC AGAGGACAAA GGTCTGGGAC ACACTCCAAC 660  
TGGCTCCGGA TCTTGGCTGG ATCGGACTCT CAGGGTGGAG GAGACACAAG CACAGCAGCT 720  
GCCCAGCGTG TGCCACGCCC TCCCACCGCT GGTCCCGGCT GCCAGGAGGC TGCCCGCTGG 780  
CGGGAAGGGG CCGGGAACCC TCAGAGCCCC GCGGAGACAG CAGCCGCCTT GTTCTCAGC 840  
CCGGTGGCTT TTTTTCGCC TGCTCTCCCA GGGGACAGAC ACCACCGCCC CACCCTCAC 900  
GCCCCACCTC CCGGGGGAT CTTTCCGCC CCAGCCCTGA AAGCGTTAAT CCGGAGCTT 960  
TCTGCACACC CCCCAGCCG TCCCGCCCAA GTTCTCTAAA AAAGAAGGT GCAAAGTTTG 1020  
GTCCAGGATA GAAAAATGAC TGATCAAGG CAGCGGATAC TTCTGTGCG CCGGACGCTA 1080  
TATATAAGT GATGAGCGCA CGGGCTCGGG AGACGACCG GAGCGCTCCG CCAGCCGCCG 1140  
CCTCCAAGCC CCTGAGGTTT CCGGGGACCA CA ATG AAC AAG TTG CTG TGC TGC 1193

Met Asn Lys Leu Leu Cys Cys

-20

20

-15

INTELLECTUAL PROPERTY OFF  
OF NZ

20 AUG 1998

330400

GCG CTC GTG GTAAGTCCCT GGGCCAGCCG ACGGGTGCCC GCGCCTGGG 1242

Ala Leu Val

GAGGCTGCTG CCACCTGGTC TCCCAACCTC CCAGCGGACC GCGGGGAGA AGGCTCCACT 1302

CGCTCCCTCC CAGG 1316

[0025]

Seq.Id.No.: 2

Length of sequence: 9898

Type of sequence: nucleic acid

Strandedness: 2

Topology: linear

Molecular type: genomic DNA (human OCIF genomic DNA-2)

Sequence:

GCTTACTTTG TGCCAAATCT CATTAGGCTT AAGGTAATAC AGGACTTTGA GTCAAATGAT 60

ACTGTTGCAC ATAAGAACAA ACCTATTTTC ATGCTAAGAT GATGCCACTG TGTTCCTTTC 120

TCCTTCTAG TTT CTG GAC ATC TCC ATT AAG TGG ACC ACC CAG GAA ACG TTT 171

Phe Leu Asp Ile Ser Ile Lys Trp Thr Thr Gln Glu Thr Phe

-10

-5

1

CCT CCA AAG TAC CTT CAT TAT GAC GAA GAA ACC TCT CAT CAG CTG TTG 219

Pro Pro Lys Tyr Leu His Tyr Asp Glu Glu Thr Ser His Gln Leu Leu

5

10

15

TGT GAC AAA TGT CCT CCT GGT ACC TAC CTA AAA CAA CAC TGT ACA GCA 267

Cys Asp Lys Cys Pro Pro Gly Thr Tyr Leu Lys Gln His Cys Thr Ala

20

25

30

35

AAG TGG AAG ACC GTG TGC GCC CCT TGC CCT GAC CAC TAC TAC ACA GAC 315

330400

Lys Trp Lys Thr Val Cys Ala Pro Cys Pro Asp His Tyr Tyr Thr Asp

40

45

50

AGC TGG CAC ACC AGT GAC GAG TGT CTA TAC TGC AGC CCC GTG TGC AAG 363

Ser Trp His Thr Ser Asp Glu Cys Leu Tyr Cys Ser Pro Val Cys Lys

55

60

65

GAG CTG CAG TAC GTC AAG CAG GAG TGC AAT CGC ACC CAC AAC CGC GTG 411

Glu Leu Gln Tyr Val Lys Gln Glu Cys Asn Arg Thr His Asn Arg Val

70

75

80

TGC GAA TGC AAG GAA GGG CGC TAC CTT GAG ATA GAG TTC TGC TTG AAA 459

Cys Glu Cys Lys Glu Gly Arg Tyr Leu Glu Ile Glu Phe Cys Leu Lys

85

90

95

CAT AGG AGC TGC CCT CCT GGA TTT GGA GTG GTG CAA GCT G GTACGTGTCA 509

His Arg Ser Cys Pro Pro Gly Phe Gly Val Val Gln Ala

100

105

110

ATGTGCAGCA AAATTAATTA GGATCATGCA AAGTCAGATA GTTGTGACAG TTTAGGAGAA 569

CACTTTTGTG CTGATGACAT TATAGGATAG CAAATTGCAA AGGTAATGAA ACCTGCCAGG 629

TAGGTACTAT GTGTCTGGAG TGCTTCCAAA GGACCAATTGC TCAGAGGAAT ACTTTGCCAC 689

TACAGGGCAA TTTAATGACA AATCTCAAAAT GCAGCAAAATT ATTCTCTCAT GAGATGCCATG 749

ATGGTTTTTT TTTTTTTTTT TAAAGAAACA AACTCAAGTT GCACTATTGA TAGTTGATCT 809

ATACCTCTAT ATTTCACITC ACCATGGACA CCTTCAAACCT GCAGCACTTT TTGACAAACA 869

TCAGAAATGT TAATTTATAC CAAGAGAGTA ATTATGCTCA TATTAATGAG ACTCTGGAGT 929

GCTAACAATA AGCAGTTATA ATTAATTATG TAAAAAATGA GAATGGTGAG GGAATTGCA 989

TTTCATTATT AAAACAAGG CTAGTTCTTC CTTTAGCATG GGAGCTGAGT GTTTGGGAGG 1049

GTAAGGACTA TAGCAGAATC TCITCAATGA GCTTATTCTT TATCTTAGAC AAAACAGATT 1109



330400

GTCAAGCCAA GAGCAAGCAC TTGCTATAA ACCAAGTGCT TTCTTTTTG CATTTTGAAC 1169  
AGCATTGGTC AGGGCTCATG TGTATTGAAT CTTTAAACC AGTAACCCAC GTTTTTTTTC 1229  
TGCCACATTT CGCAAGCTTC AGTGCAGCCT ATAACCTTTC ATAGCTTGAG AAAATTAAGA 1289  
GTATCCACTT ACTTAGATGG AAGAAAGTAAT CAGTATAGAT TCTGATGACT CAGTTTGAAG 1349  
CAGTGTTTCT CAACTAAGC CCTGCTGATA TTTAAGAAA TATCTGGATT CCTAGGCTGG 1409  
ACTCCTTTTT GTGGGCAGCT GTCTGCGCA TTGTAGAAIT TTGGCAGCAC CCCTGGACTC 1469  
TAGCCACTAG ATACCAATAG CAGTCTCTCC CCCATGTGAC AGCCAAAAT GTCTTCAGAC 1529  
ACTGTCAAAAT GTGCCAGCT GGCAAAATCA CTCTGGTTG AGAACAGGGT CATCAATGCT 1589  
AAGTATCTGT AACTATTTTA ACTCTCAAAA CTGTGATAT ACAAAGTCTA AATTATTAGA 1649  
CGACCAATAC TTAGGTTTA AAGGCATACA AATGAAACAT TCAAAAATCA AAATCTATTC 1709  
TGTTTCTCAA ATAGTGAATC TTATAAAAT AATCACAGAA GATGCAAAAT GCATCAGAGT 1769  
CCCTTAAAT TCTCTTGT ATGAGTATTT GAGGGAGGAA TTGGTGATAG TTCTACTTT 1829  
CTATTGGATG GTACTTTGAG ACTCAAAAGC TAAGCTAAGT TGTGTGTGTG TCAGGGTGG 1889  
GGGTGTGGAA TCCCATCAGA TAAAAGCAAA TCCATGTAAT TCATTCAGTA AGTTGTATAT 1949  
GTAGAAAAT GAAAAGTGG CTATGCAGCT TGGAACTAG AGAATTTTGA AAAATAATGG 2009  
AAATCACAAG GATCTTTCTT AAATAAGTAA GAAATCTGT TTGTAGAATG AAGCAAGCAG 2069  
GCAGCCAGAA GACTCAGAAC AAAAGTACAC ATTTACTCT GTGTACACTG GCAGCACAGT 2129  
GGGATTIATT TACCTCTCC TCCCTAAAA CCCACACAGC GGTTCCTCTT GGGAAATAAG 2189  
AGGTTTCAG CCCAAGAGA AGGAAAGACT ATGTGGTGT ACTCTAAAA GTATTTAATA 2249  
ACCGTTTTGT TGTGCTGTT GCTGTTTGA AATCAGATTG TCTCTCTCC ATATTTIATT 2309  
TACTTCATTG TGTTAATTC TGTGGAATTA CTIAGAGCAA GCATGGTGAA TTCTCAACTG 2369  
TAAAGCCAAA TTCTCCATC ATTATAATTT CACATTTTGC CTGGCAGGTT ATAATTTTAA 2429  
TATTTCACCT GATAGTAATA AGGTAAAATC ATTACTTAGA TGGATAGATC TTTTTCATAA 2489  
AAAGTACCAT CAGTATAGA GGAAGTCAT GTTCATGTT AGGAAGTCA TTAGATAAAG 2549  
CTTCTGAATA TATATGAAA CATTAGTTCT GTCATCTTA GATTCTTTT GTTAAATAAC 2609  
TTTAAAGCT AACTTACCTA AAAGAAATAT CTGACACATA TGAAGTCTC ATTAGGATGC 2669  
AGGAGAAGAC CCAAGCCACA GATATGTATC TGAAGATGA ACAAGATTCT TAGGCCCCGG 2729  
ACGGTGGCTC ACATCTGTAA TCTCAAGACT TTGAGAGTC AAGCGGGCA GATCACTGA 2789  
GGTCAGGAGT TCAAGACCAG CTGCGCCAAC ATGATGAAAC CTGCTCTTA CTAAAAATAC 2849

330400

AAAAATTAGC AGGGCATGGT GGTGCATGCC TGCACCCCTA GCTACTCAGG AGGCTGAGAC 2909  
AGGAGAATCT CTTC AACCTT CGAGGCGGAG GTTGTGGTGA GCTGAGATCC CTCTACTGCA 2969  
CTCCAGCCGT GGTGACAGAG ATGAGACTCC GTCCCTGCCG CCGCCCCCGG CTCCCCCCCC 3029  
AAAAAGATTCTTTTCATGC AGAACATAGC GCAGTCAACA AAGGGAGACC TGGGTCCAGG 3089  
TGTCCAAGTC ACTTATTTCG AGTAAATTAG CAATGAAAGA ATGCCATGGA ATCCCTGCCC 3149  
AAATACCTCT GCTTATGATA TTGTAGAATT TGATATAGAG TTGTATCCCA TTAAAGGAGT 3209  
AGGATGTAGT AGGAAAGTAC TAAAAACAAA CACACAAACA GAAAACCCCTC TTGTCTTTGT 3269  
AAGTGCTTC CTAAGATAAT GTCAGTGCAA TGCTCGAAAT AATATTTAAT ATGTGAAGGT 3329  
TTTAGGCTGT GTTTTCCCTT CCTGTTCTTT TTTTCTGCCA GGCCTTTGTC ATTTTTCGAG 3389  
GTCAATGAAT CATGTAGAAA GAGACAGGAG ATGAACTAG AACCAGTCCA TTTTCCCCCT 3449  
TTTTTTIATTT TCTGGTTTTG GTAAAAGATA CAATGAGGTA GGAAGTTCAG ATTTATAAAT 3509  
GAAGTTIAT AAGTTTCTGT AGCTTTGATT TTCTCTTTC ATATTGTGTA TCTTGCATAA 3569  
GCCAGAAATG GCCTGTAAAA TCTACATATG GATATTGAAG TCTAAATCTG TTCAACTAGC 3629  
TTACACTAGA TGGAGATATT TTCATATTCA GATACACTGG AATGTATGAT CTAGCCATGC 3689  
GTAATATAGT CAAGTGTTTG AAGGTATTTA TTTTAAATAG CGTCTTTAGT TGTGGACTGG 3749  
TTCAAGTTTT TCTGCCAATG ATTTCTTCAA ATTTATCAAA TATTTTCCA TCATGAAGTA 3809  
AAATGCCCTT GCAGTCACCC TTCTGAAGT TTGAACGACT CTGCTGTTTT AAACAGTTTA 3869  
AGCAAATGGT ATATCATCTT CCGTTTACTA TGTAGCTTAA CTGAGGCTT ACGCTTTTGA 3929  
GTCAGCGGCC AACTTTATTG CCACCTTCAA AAGTTTATTA TAATGTTGTA AATTTTACT 3989  
TCTCAAGGTT AGCATACTTA GGAGTTGCTT CACAATTAGG ATTGAGGAAA GAAAGAAGTT 4049  
CAGTAGGAAC TGATTGGAAT TTAATGATGC AGCATTCAT GGGTACTAAT TTCAAAGAAT 4109  
GATATTACAG CAGACACACA GCAGTTATCT TGATTTTCTA GGAATAATTG TATGAAGAAT 4169  
ATGGCTGACA ACACGGCCTT ACTGCCACTC AGCGGAGGCT GGACTAATGA ACACCCTACC 4229  
CTTCTTTCCT TTCCTCTCAC ATTTCATGAG CGTTTGTAG GTAACGAGAA AATTGACTTG 4289  
CATTTGCATT ACAAGGAGGA GAAACTGGCA AAGGGGATGA TGGTGAAGT TTTGTTCTGT 4349  
CTAATGAAGT GAAAAATGAA AATGCTAGAG TTTTGTGCAA CATAATAGTA GCAGTAAAAA 4409  
CCAAGTGAAA AGTCTTTCCA AAAGTGTTT AAGAGGGCAT CTGTGGGAA ACGATTTGAG 4469  
GACAAGGTAC TAAATTGCTT GGTATTTTCC GTAG GA ACC CCA GAG CGA AAT ACA 4523

Gly Thr Pro Glu Arg Asn

20 AUG 1998

RECEIVED

330400

115

GTT TGC AAA AGA TGT CCA GAT GGG TTC TTC TCA AAT GAG ACG TCA TCT 4571  
 Val Cys Lys Arg Cys Pro Asp Gly Phe Phe Ser Asn Glu Thr Ser Ser  
 120 125 130 135

AAA GCA CCC TGT AGA AAA CAC ACA AAT TGC ACT GTC TTT GGT CTC CTG 4619  
 Lys Ala Pro Cys Arg Lys His Thr Asn Cys Ser Val Phe Gly Leu Leu  
 140 145 150

CTA ACT CAG AAA GGA AAT GCA ACA CAC GAC AAC ATA TGT TCC GGA AAC 4667  
 Leu Thr Glu Lys Gly Asn Ala Thr His Asp Asn Ile Cys Ser Gly Asn  
 155 160 165

AGT GAA TCA ACT CAA AAA TGT GGA ATA G GTAATTACAT TCCAAAATAC 4715  
 Ser Glu Ser Thr Glu Lys Cys Gly Ile  
 170 175

GTCTTTGTAC GATTTTGTAG TATCATCTCT CTCTCTGAGT TGAACACAAG GCCTCCAGCC 4775  
 ACATCTCTGG TCAAACCTAC ATTTTCCCTT TCTTGAATCT TAAACAGCTA AGGCTACTCT 4835  
 CGATGCATTA CTGTAAAGC TACCACTCAG AATCTCTCAA AAACCTCATCT TCTCACAGAT 4995  
 AACACCTCAA AGCTTGATTT TCTCTCCTTT CACACTGAAA TCAAATCTTG CCCATAGGCA 4955  
 AAGGGCAGTG TCAAGTTTGC CACTGACATG AAATTAGGAG AGTCCAAACT GTAGAATTCA 5015  
 CGTTGTGTGT TATTACTTTC ACGAATGTCT GTATTATTAA CTAAGIATA TATTGGCAAC 5075  
 TAAGAAGCAA AGTGATATAA ACATGATGAC AAATTAGGCC AGGCATGGTG GCTTACTCCT 5135  
 ATAATCCCAA CATTTTGGGG GGCCAAGGTA GGCAGATCAC TTGAGGTGAG GATTTCAGA 5195  
 CCAGCCTGAC CAACATGGTG AAACCTTGTC TCTACTAAAA ATACAAAAAT TAGCTGGCCA 5255  
 TGGTAGCAGG CACTTCTIAGT ACCAGCTACT CAGGGCTGAG CGCAGAGAAT CCCTTGAACC 5315  
 CAGGAGATGG AGCTTGCACT GAGCTGAGAT TGTACCCTG CACTCCAGTC TCGGCAACAG 5375

330400

AGCAAGATTT CATCACACAC ACACACACAC ACACACACAC ACACATTAGA AATGTGTA 5435  
 TGGCTTTGTT ACCTATGGTA TTAGTCCATC TATTGCATGG AACTTCCAAG CTACTCTGGT 5495  
 TGTGTTAAGC TCTTCATTGG GTACAGGTCA CTAGTATTAA GTTCAGGTTA TTCGGATGCA 5535  
 TTCCACGGTA GTGATGACAA TTCATCAGGC TAGTGTGTGT GTTCACCTTG TCACTCCAC 5615  
 CACTAGACTA ATCTCAGACC TTCACTCAA GACACATTAC ACTAAAGATG ATTTCCTTTT 5675  
 TTGTGTTTAA TCAAGCAATG GTATAACCA GCTTGACTCT CCCCAAACAG TTTTCGTAC 5735  
 TACAAAGAAG TTTATGAAGC AGAGAAATGT GAATTCATAT ATATATGACA TTCTAACCA 5795  
 GTTCCAGCAT TGTTCATTG TGTAATTGAA ATCATAGACA AGCCATTITA GCCTTTGCTT 5855  
 TCTTATCTAA AAAAAAAAAA AAAAAATGA AGGAAGGGGT ATTAAGGGA GTGATCAAT 5915  
 TTTAACATTC TCTTAAATTA ATTCATTTTT AATTTTACTT TTTTTCATT ATTGTGCACT 5975  
 TACTATGTGG TACTGTGCTA TAGAGGCTTT AACATTATA AAAACACTGT GAAAGTGTCT 6035  
 TCAGATGAAT ATAGGTAGTA GAACGGCAGA ACTAGIATTC AAAGCCAGGT CTGATGAATC 6095  
 CAAAAACAAA CACCCATTAC TCCCATTTC TGGACATAC TTA CTCTACC CAGATGCTCT 6155  
 GGGCTTTGTA ATGCTATGT AAATAACATA GTTTTATGTT TGGTATTTT CCTATGTAAT 6215  
 GTCTACTTAT ATATCTGAT CTATCTCTTG CTTTGTTC AAAGGTAAAC TATGTGCTA 6275  
 AATGTGGGCA AAAATAACA CACTATTCCA AATTACTGTT CAAATTCCTT TAAGTCAGTG 6335  
 ATAATATTT GTTTTGACAT TAATCATGAA GTTCCCTGTG GGTACTAGGT AAACCTTTAA 6395  
 TAGAATGTIA ATGTTTGTAT TCATTATAAG AATTTTGGC TGTACTTAT TTACAACAT 6455  
 ATTTCACTCT AATTAGACAT TTAATAACT TTCTTTGAA AACATGCCC AAAAAAGAC 6515  
 ATTAGAAGAC ACGTAAGCTC AGTTGGTCTC TGCCACTAAG ACCAGCCAAC AGAAGCTGA 6575  
 TTTTATTCAA ACTTTGCATT TTAGCATATT TTACTTTGGA AAATCAATT GTTGTGGTT 6635  
 TTTGTTTTG TTTGTATGA ATAGACTCTC AGAAATCCAA TTGTGAGTA AATCTTCTGG 6695  
 GTTTTCTAAC CTTTCTTAG AT GTT ACC CTG TGT GAG GAG GCA TTC TTC AGG 6747

Asp Val Thr Leu Cys Glu Glu Ala Phe Phe Arg

180

185

TTT GCT GTT CCT ACA AAG TTT ACG CCT AAC TGG CTT AGT GTC TTG GTA 6795

Phe Ala Val Pro Thr Lys Phe Thr Pro Asn Trp Leu Ser Val Leu Val

190

195

200

INTELLECTUAL PROPERTY OFFICE  
OF NZ

20 AUG 1998

RECEIVED

330400

GAC AAT TTG CCT GGC ACC AAA GTA AAC GCA GAG AGT GTA GAG AAG ATA 6843

Asp Asn Leu Pro Gly Thr Lys Val Asn Ala Glu Ser Val Glu Arg Ile

205

210

215

AAA CGG CAA CAC AGC TCA CAA CAA CAG ACT TTC CAG CTG CTG AAG TTA 6891

Lys Arg Gln His Ser Ser Gln Glu Gln Thr Phe Gln Leu Leu Lys Leu

220

225

230

235

TGG AAA CAT CAA AAC AAA GAC CAA GAT ATA GTC AAG AAG ATC ATC CAA G 6940

Trp Lys His Gln Asn Lys Asp Gln Asp Ile Val Lys Lys Ile Ile Gln

240

245

250

GTATGATAAT CTAAATAAA AAGATCAATC AGAAATCAAA GACACCTATT TATCATAAAC 7000  
 CAGGAACAAG ACTGCATGTA TGTTTAGTTG TGTGGATCTT GTTTCCTGT TGGAAATCAT 7060  
 GTTGGACTGA AAAAGTTTCC ACCTGATAAT GTAGATGTGA TTCCACAAC AGTTATACAA 7120  
 GGTTTTGTTT TCACCCCTGC TCCCAGTITT CTTGTAAAG TATGTTGAAC ACTCTAAGAG 7180  
 AAGAGAAATG CATTGAAGG CAGGGCTGTA TCTCAGGGAG TCGCTTCCAG ATCCCTTAAC 7240  
 GCTTCTGTA GCAGCCCTC TAGACCACCA AGGAGAAGCT CTATAACCA TTTGTATCTT 7300  
 ACATTGCAC TCTACCAAGA AGCTCTGTTG TATTACTTGT GTAATTCTCT CCAGGTAGGC 7360  
 TTTTCGTAGC TTACAAATAT GTTCTTATTA ATCCTCATGA TATGCTCTGC ATTAAATTA 7420  
 TTTTAATGCC ATATGTTATG AGAATTAATG AGATAAAATC TGAAAAGTGT TTGAGCCTCT 7480  
 TGTAGGAAAA AGCTAGTTAC AGCAAAATGT TCTCATCTCT TATAAGTTTA TATAAGATT 7540  
 CTCCTTTAGA AATGGTGTGA GAGAGAAACA GAGAGAGATA GGGAGAGAAG TGTGAAAGAA 7600  
 TCTGAAGAAA AGGAGTTTCA TCCAGTGTGG ACTGTAAGCT TTACGACACA TGATGGAAG 7660  
 AGTTCTGACT TCAGTAAGCA TTGGGAGGAC ATGCTAGAAG AAAAAGGAAG AAGAGTTTCC 7720  
 ATAATGCAGA CAGGTCAGT GAGAAATTC TACAGTCTCT CACCAGTAGT TAAATGACTG 7780  
 TATAGTCTTG CACTACCTTA AAAAATTC TATATCTGAA ACCGGGGCAA CAGATTTTAG 7840  
 GAGACCAACG TCTTGAGAG CTGATTGCTT TTGCTTATGC AAAGAGTAA CTTTATGTT 7900

330400

TTGACCAAC CAAAGTATT CTTTGAACGT ATAATTAGCC CTGAAGCCGA AAGAAAAGAG 7960  
 AAAATCAGAG ACCGTTAGAA TTGGAAGCAA CCAAATTCCC TATTTTATAA ATGAGGACAT 8020  
 TTAAACCCAG AAAGATGAAC CGATTITGGCT TAGGGCTCAC AGATACTAAG TGACTCATGT 8080  
 CATTAATAGA AATGTTAGTT CCTCCCTCTT AGGTTGTAC CCTAGCTTAT TACTGAAATA 8140  
 TTCTCTAGCG TGTGTGTCCT CTTTACTGCC TCGACCTCAT GTCTTTGAGT TTTCAGATAT 8200  
 CCTCCTCATG GAGGTAGTCC TCTGGTGCTA TGTGTATTCT TTAAGGCTA GTTACGGCAA 8260  
 TTAACCTTATC AACTAGCGCC TACTAATGAA ACTTTGTATT ACAAAGTAGC TAACTTGAAT 8320  
 ACTTTCCTTT TTTTCTGAAA TGTATGGTG GTAATTTCTC AAACCTTTTC TTAGAAAACT 8380  
 GAGAGTGATG TGTCTTATTT TCTACTGTAA ATTTTCAAAA TTAGGAGCTT CTTCCAAAGT 8440  
 TTTGTTGGAT GCCAAAAATA TATAGCATAT TATCTTATTA TAACAAAAAA TATTTATCTC 8500  
 AGTTCCTAGA AATAAATGGT GTCACCTAAC TCCTCTCAA AAGAAAAAGT TATCATTGAA 8560  
 ATATAATTAT GAAATTCCTC AAGAACCCTT TGCTCAGCG TTGTTTATG ATGCCATTGG 8620  
 ATGAATATAA ATGATGTGAA CACTTATCTG GGCCTTTTGT TTATGCGA AT ATT GAC 8676

Asp Ile Asp

CTC TGT GAA AAC AGC GTG CAG CGG CAC ATT GGA CAT GCT AAC CTC ACC 8724  
 Leu Cys Glu Asn Ser Val Gln Arg His Ile Gly His Ala Asn Leu Thr  
 255 260 265 270

TTC GAG CAG CTT CGT AGC TTG ATG GAA AGC TTA CCG GGA AAG AAA GTG 8772  
 Phe Glu Gln Leu Arg Ser Leu Met Glu Ser Leu Pro Gly Lys Lys Val  
 275 280 285

GGA GCA GAA GAC ATT GAA AAA ACA ATA AAG GCA TGC AAA CCC AGT GAC 8820  
 Gly Ala Glu Asp Ile Glu Lys Thr Ile Lys Ala Cys Lys Pro Ser Asp  
 290 295 300

CAG ATC CTG AAG CTG CTC AGT TTG TGG CGA ATA AAA AAT GGC GAC CAA 8863  
 Gln Ile Leu Lys Leu Leu Ser Leu Trp Arg Ile Lys Asn Gly Asp Gln

330400

305

310

315

GAC ACC TTG AAG GGC CTA ATG CAC GCA CTA AAG CAC TCA AAG ACG TAC 8916

Asp Thr Leu Lys Gly Leu Met His Ala Leu Lys His Ser Lys Thr Tyr

320

325

330

CAC TTT CCC AAA ACT GTC ACT CAG AGT CTA AAG AAG ACC ATC AGG TTC 8964

His Phe Pro Lys Thr Val Thr Gln Ser Leu Lys Lys Thr Ile Arg Phe

335

340

345

350

CTT CAC AGC TTC ACA ATG TAC AAA TTG TAT CAG AAG TTA TTT TTA GAA 9012

Leu His Ser Phe Thr Met Tyr Lys Leu Tyr Gln Lys Leu Phe Leu Gln

355

360

365

ATG ATA GGT AAC CAG GTC CAA TCA GTA AAA ATA AGC TGC TTA 9054

Met Ile Gly Asn Gln Val Gln Ser Val Lys Ile Ser Cys Leu

370

375

380

TAACTGGAAA TGGCCATTGA GCTGTTTCCT CACAATTGGC GAGATCCCAT GGATGAGTAA 9114

ACTGTTTCTC AGGCACTTGA GGCTTTCAGT GATATCTTTC TCATTACCAG TGACTAATTT 9174

TGCCACAGGG TACTAAAAGA AACTATGATG TGGAGAAAGG ACTAACATCT CCTCCAATAA 9234

ACCCCAAATG GTTAATCCAA CTGTCAGATC TGGATCGTTA TCTACTGACT ATATTTTCCC 9294

TTATTACTGC TTGCAGTAAT TCAACTGGAA ATTAAAAAAA AAAAAGTAGA CTCCACTGGG 9354

CCTTACTAAA TATGGGAATG TCTAACTTAA ATAGCTTTGG GATTCAGCT ATGCTAGAGG 9414

CTTTTATTAG AAAGCCATAT TTTTTCTGT AAAAGTTACT AATATATCTG TAACACTATT 9474

ACAGTATTGC TATTTATATT CATTCAGATA TAAGATTGG ACATATTATC ATCCTATAAA 9534

GAAACGGTAT GACTTAATTT TAGAAAGAAA ATTATATTCT GTTTATTATG ACAAATGAAA 9594

GAGAAATAT ATATTTTAA TGAAAAGTTT GTAGCATTT TCTAATAGST ACTGCCATAT 9654

TTTTCTGTGT GGAGTATTTT TATAATTTTA TCTGTATAAG CTGTAATATC ATTTTATAGA 9714

330400

AAATGCATT TTTAGTCAAT TGTTTAATGT TGGAAAACAT ATGAAATATA AATTATCTGA 9774  
 ATATTAGATG CTCTGAGAAA TTGAATGTAC CTTATTTAAA ACATTTTATG GTTTTATAAC 9834  
 TATATAAATG ACATTATTAA AGTTTTCAAA TTATTTTITA TTGCTTTCTC TGTIGCTTTT 9894  
 ATTT

[0026]

Seq.Id.No.: 3

Length of sequence: 401

Type of sequence: amino acid

Strandedness: 1

Topology: linear

Molecular type: protein

Sequence:

Met Asn Asn Leu Leu Cys Cys Ala Leu Val Phe Leu Asp Ile Ser  
 -20 -15 -10  
 Ile Lys Trp Thr Thr Gln Glu Thr Phe Pro Pro Lys Tyr Leu His  
 -5 1 5  
 Tyr Asp Glu Glu Thr Ser His Gln Leu Leu Cys Asp Lys Cys Pro  
 10 15 20  
 Pro Gly Thr Tyr Leu Lys Gln His Cys Thr Ala Lys Trp Lys Thr  
 25 30 35  
 Val Cys Ala Pro Cys Pro Asp His Tyr Tyr Thr Asp Ser Trp His  
 40 45 50  
 Thr Ser Asp Glu Cys Leu Tyr Cys Ser Pro Val Cys Lys Glu Leu  
 55 60 65  
 Gln Tyr Val Lys Gln Glu Cys Asn Arg Thr His Asn Arg Val Cys  
 70 75 80  
 Glu Cys Lys Glu Gly Arg Tyr Leu Glu Ile Glu Phe Cys Leu Lys  
 85 90 95  
 His Arg Ser Cys Pro Pro Gly Phe Gly Val Val Gln Ala Gly Thr



330400

100	105	110
Pro Glu Arg Asn Thr Val Cys Lys Arg Cys Pro Asp Gly Phe Phe		
115	120	125
Ser Asn Glu Thr Ser Ser Lys Ala Pro Cys Arg Lys His Thr Asn		
130	135	140
Cys Ser Val Phe Gly Leu Leu Leu Thr Gln Lys Gly Asn Ala Thr		
145	150	155
His Asp Asn Ile Cys Ser Gly Asn Ser Glu Ser Thr Gln Lys Cys		
160	165	170
Gly Ile Asp Val Thr Leu Cys Glu Glu Ala Phe Phe Arg Phe Ala		
175	180	185
Val Pro Thr Lys Phe Thr Pro Asn Trp Leu Ser Val Leu Val Asp		
190	195	200
Asn Leu Pro Gly Thr Lys Val Asn Ala Glu Ser Val Glu Arg Ile		
205	210	215
Lys Arg Gln His Ser Ser Gln Glu Gln Thr Phe Gln Leu Leu Lys		
220	225	230
Leu Trp Lys His Gln Asn Lys Asp Gln Asp Ile Val Lys Lys Ile		
235	240	245
Ile Gln Asp Ile Asp Leu Cys Glu Asn Ser Val Gln Arg His Ile		
250	255	260
Gly His Ala Asn Leu Thr Phe Glu Gln Leu Arg Ser Leu Met Glu		
265	270	275
Ser Leu Pro Gly Lys Lys Val Gly Ala Glu Asp Ile Glu Lys Thr		
280	285	290
Ile Lys Ala Cys Lys Pro Ser Asp Gln Ile Leu Lys Leu Leu Ser		
295	300	305
Leu Trp Arg Ile Lys Asn Gly Asp Gln Asp Thr Leu Lys Gly Leu		
310	315	320

330400

Met His Ala Leu Lys His Ser Lys Thr Tyr His Phe Pro Lys Thr

325

330

335

Val Thr Gln Ser Leu Lys Lys Thr Ile Arg Phe Leu His Ser Phe

340

345

350

Thr Met Tyr Lys Leu Tyr Gln Lys Leu Phe Leu Glu Met Ile Gly

355

360

365

Asn Gln Val Gln Ser Val Lys Ile Ser Cys Leu

370

375

380

330400

{0027}

Seq.Id.No.: 4

Length of sequence: 1206

Type of sequence: nucleic acid

Strandedness: 1

Topology: linear

Molecular type: cDNA

Sequence:

ATGAACAACT TGCTGTGCTG CGCGCTCGTG TTTCTGGACA TCTCCATTAA GTGGACCACC 60  
CAGGAAACGT TTCTCCAAA GTACCTTCAT TAIGACGAAG AAACCTCTCA TCAGCTGTTG 120  
TGTGACAAAT GTCTCTCTGG TACCTACCTA AAACAACACT GTACAGCAAA GTGGAAGACC 180  
GTGTCCGCCC CTTGCCCTGA CCACTACTAC ACAGACAGCT GGCACACCAG TGACGAGTGT 240  
CTATACTGCA GCCCCGTGTG CAAGGAGCTG CAGTACGTCA AGCAGGAGTG CAATCCGACC 300  
CACAACCGCG TGTGCGAATG CAAGGAAGGG CGCTACCTTG AGATAGAGTT CTGCTTGAAA 360  
CATAGGAGCT GCCCTCTCGG ATTTGGAGTG GTCCAAGCTG GAACCCGAGA GCGAAATACA 420  
GTTTGCAAAA GATGTCCAGA TGGGTTCTTC TCAATGAGA CGTCATCTAA AGCACCCTGT 480  
AGAAAAACACA CAAATTGCAG TGTCTTTGGT CTCCTGCTAA CTCAGAAAGG AAATGCAACA 540  
CAGGACAACA TATGTTCCGG AACAGTGAA TCAACTCAA AAATGTGGAAT AGATGTTACC 600  
CTGTGTGAGG AGGCATTCTT CAGGTTTGCT GTTCTACAA AGTTTACGCC TAACTGGCTT 660  
AGTGCTCTTG TAGACAAATT GCCTGGCACC AAAGTAAAGC CAGAGAGTGT AGAGAGGATA 720  
AAACGGCAAC ACAGCTCACA AGAACAGACT TTCCAGCTGC TGAAGTTATG CAAACATCAA 780  
AACAAAGACC AAGATATAGT CAGAAGATC ATCCAAGATA TTGACCTCTG TGAAGACAGC 840  
GTGCAGCGGG ACATTGACA TGCTAACCTC ACCTTCGAGC AGCTTCGTAG CTTGATGGAA 900  
AGCTTACCGG GAAAGAAAGT GCGAGCAGAA GACATTGAAA AAACAATAAA CCGATGCAAA 960  
CCGAGTACC AGATCCTGAA GCTGCTCAGT TTGTGGCGAA TAAAAAATGG CGACCAAGAC 1020  
ACCTTGAAAG GCCTAATGCA CGCACTAAAG CACTCAAGA CGTACCACTT TCCAAAACCT 1080  
GTCACTCAGA GTCTAAGAA GACCATCAGG TTCTTCACA GCTTCACAA GTACAAATTT 1140  
TATCAGAAAT TATTTTTAGA AATGATAGGT AACCAAGTCC AATCAGTAAA AATAAGCTGC 1200  
TTATAA

330400

## [Brief Description of the Drawing]

## [Figure 1]

It exhibits the result of Western blotting of the protein obtained by the expression of the genomic DNA of the present invention in example 3(iii)

## [Explanation of Referenced Numerals]

- 1: marker
- 2: supernatant of culture medium of COS-7 cell transfected with vector pWESRaOCIF (example 3(iii))
- 3: supernatant of culture medium of COS-7 transfected with vector pWESR  $\alpha$  (control)

330400

[Document] Abstract

[Abstract]

[Problems to be Solved]

A novel DNA encoding a protein having an inhibitory activity on osteoclast formation and a method of preparing said protein thereby.

[Means to Solve the Problems]


DNA described in Seq.ID.No.1 and 2.

A method of preparing a protein with a molecular weight of about 60 kD (under reducing conditions), and about 60 kD and about 120 kD (under non-reducing conditions) having an inhibitory action on osteoclast formation by inserting said DNA into expression vector and by genetic engineering manipulation. This protein has an inhibitory action on osteoclast formation and can be useful for curing osteoporosis and rheumatism.

[Selected Drawings] None

330400

[Figure 1]



13  
330400CLAIMS:

1. A DNA comprising the nucleotide sequences of the Sequences No. 1 and No. 2 in the Sequence Table.

2. The DNA according to claim 1, wherein the Sequence ID No. 1 includes the first exon of the OCIF gene and the Sequence ID No. 2 includes the second, third, fourth, and fifth exons.

3. A protein exhibiting the activity of inhibiting differentiation and/or maturation of osteoclasts and having the following physicochemical characteristics,

(a) molecular weight (SDS-PAGE):

(i) Under reducing conditions: about 60 kD,

(ii) Under non-reducing conditions: about 60 kD and about 120 kD;

(b) amino acid sequence:

includes an amino acid sequence of the Sequence ID No. 3 in the Sequence Table,

(c) affinity:

exhibits affinity to a cation exchanger and heparin, and

(d) heat stability:

(i) the osteoclastogenesis-inhibitory activity is reduced when treated with heat at 70°C for 10 minutes or at 56°C for 30 minutes,

(ii) the osteoclastogenesis-inhibitory activity is lost when treated with heat at 90°C for 10 minutes.

4. A process for producing a protein exhibiting an

380400

activity of inhibiting differentiation and/or maturation of osteoclasts and having the following physicochemical characteristics,

(a) molecular weight (SDS-PAGE):

- (i) Under reducing conditions: about 60 kD,
- (ii) Under non-reducing conditions: about 60 kD and about 120 kD;

(b) amino acid sequence:

includes an amino acid sequence of the Sequence ID No. 3 of the Sequence Table,

(c) affinity:

exhibits affinity to a cation exchanger and heparin, and

(d) heat stability:

- (i) the osteoclastogenesis-inhibitory activity is reduced when treated with heat at 70°C for 10 minutes or at 56°C for 30 minutes,

- (ii) the osteoclastogenesis-inhibitory activity is lost when treated with heat at 90°C for 10 minutes,

the process comprising inserting a DNA including the nucleotide sequences of the sequences No. 1 and No. 2 in the Sequence Table into an expression vector, producing a vector capable of expressing a protein having the above-mentioned physicochemical characteristics and exhibiting the activity of inhibiting differentiation and/or maturation of osteoclasts, and producing this protein by a genetic engineering technique.

INTELLECTUAL PROPERTY OFFICE  
OF NZ

26 AUG 1998

RECEIVED



330400

5. The use of a DNA comprising the nucleotide sequences of the sequences No.1 and No.2 in the Sequence table, in the preparation of a medicament for the treatment of osteoporosis and rheumatism.

Snow Brand Milk Product Co. Ltd

By its attorneys

  
**JAMES & WELLS**

29 MAR 1999